
11 June 2026
read more
Nuvisan´s Centre of Excellence Discovery in Berlin announces the winners of the 3rd Drug Discovery Innovation Challenge.
learn more
With the acquisition of the remaining 51% shares by ALS, we are excited to join the ALS group and contribute to strengthening its pharmaceutical footprint in Europe.
learn more
Since March 2024, Nuvisan has become the first Gyrolab® certified CRO in the EU.